Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 01, 2015 8:54 PM ET

Biotechnology

Company Overview of Renovar, Inc.

Company Overview

Renovar, Inc. engages in the discovery and development of diagnostic tests based on a portfolio of protein biomarkers for kidney disease and transplant monitoring. It provides a portfolio of protein biomarkers that indicate kidney injury using its urinary immunoassay platform; and CFSE Flow Kit that is used for tracking eight generations of cell proliferation in-vivo and in-vitro for mouse and human cells by flow cytometry. The company also offers custom assays and study services to support research activities, including biomarker selection and assay panel development, study design, data analysis, and samples testing. Renovar, Inc. was founded in 1999 and is headquartered in Appleton, Wiscon...

200 East Washington

Appleton, WI 54911

United States

Founded in 1999

Phone:

608-441-2871

Fax:

608-441-2872

Key Executives for Renovar, Inc.

Chief Executive Officer, President and Director
Co-Founder, Chairman of the Board and Chief Scientific Officer
Co-Founder
Co-Founder, Vice President and Director
Compensation as of Fiscal Year 2014.

Renovar, Inc. Key Developments

ViveBio Enters Licensing Agreement with Renovar for Novel Urine Based Biomarker Technologies Covering Kidney Disease and Transplant Monitoring

ViveBio, LLC announced that it has signed a worldwide exclusive licensing agreement with Renovar, Inc. for urine based biomarkers to predict and monitor kidney diseases as well as rejection in transplant recipients. Based upon unique inflammatory protein signatures found in the urine of diseased or injured kidney's, the Renovar technology can be used to assess the health of a patients kidney's, guide therapeutic decision making and help stratify patients by risk for developing acute rejection. Based upon an NIH sponsored, prospective, multicenter study of 280 kidney transplant recipients researchers evaluated the urinary levels of nine messenger RNAs and two proteins which are known to be associated with kidney transplant rejection. They identified Monokine induced by interferon-gamma (MIG) messenger RNA (mRNA) and MIG protein as the clinically significant biomarkers. After further testing, the researchers found that MIG protein was better at ruling out rejection than any of the mRNA's tested. It was also capable of identifying patients likely to have stable long-term kidney function and identify those patients who were unlikely to experience rejection or loss of kidney function over the next 18 months. The investigators noted that urinary MIG protein levels began to increase up to 30 days before clinical signs of kidney injury.

Similar Private Companies By Industry

Company Name Region
Boston Biomedical, Inc. United States
NGM Biopharmaceuticals, Inc. United States
KinoDyn, Inc. United States
GeneTrol Biotherapeutics, Inc. United States
Tonbo Biotechnologies Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Renovar, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.